TP53 and glioblastoma: The potential antitumor activity of LEV might be due to the inhibition of MGMT transcription and expression in glioblastoma cell lines by increasing p53 binding on the MGMT promoter, thus sensitizing glioblastoma cells to the alkylating agent TMZ [16].